11.04.25 - news

AVEO Oncology, an LG Chem company, and HiberCell Enter Into an Exclusive Development and Option Agreement for First-in-Human Compound

Read More

05.27.25 - news

HiberCell Announces Successful Completion of Dose Escalation and Enrollment Update for Ph1b Study Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in Advanced ccRCC

Read More

04.28.25 - news

HiberCell’s Board of Directors Appoints Steven Gillis, Ph.D., the Company’s Current Chairman of the Board, as Chairman and Acting CEO

Read More

05.28.24 - news

HiberCell Announces First Patient Dosed in Phase 1b Clinical Trial, Evaluating HC-7366 in Combination with Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia (AML)

Read More

04.14.26 - news

HiberCell to Present Preclinical Data Demonstrating the Enhanced Antitumor Activity of HC-7366 in Combination with VEGFR-TKIs in Clear Cell Renal Cell Carcinoma (ccRCC)

Read More

05.01.24 - news

HiberCell Announces First Patient Dosed in Clinical Collaboration with Merck, Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in patients with advanced ccRCC

Read More

12.15.23 - publication

Activation of GCN2 By HC-7366 Results in Significant Anti-Tumor Efficacy As Monotherapy and Overcomes Resistance Mechanisms When Combined with Venetoclax in AML

Poster

Read More

12.05.23 - news

HiberCell, Inc. Announces Clinical Collaboration with Merck to Evaluate HC-7366, an Activator of ISR Kinase GCN2, in Combination with WELIREG® (belzutifan) in a Phase 1b Study of Patients with Clear Cell Renal Cell Carcinoma (ccRCC)

Read More

11.27.23 - news

HiberCell Announces Successful Completion and Interim Results of Phase 1 Study of Novel PERK Inhibitor, HC-5404, in Solid Tumors and Maps Forward Path as Monotherapy and in Combinations

Read More

09.19.23 - publication

PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors

Publication

Read More

04.19.23 - publication

Activation of GCN2 by HC-7366 results in significant antitumor efficacy as monotherapy

Poster

Read More

04.18.23 - publication

Inhibition of PERK by HC-5404 sensitizes clear cell renal cell carcinoma tumor models

Poster

Read More

04.17.23 - publication

Combination therapy using PERK and PD1/PD-L1 inhibitors reduces tumor burden

Poster

Read More

03.27.23 - news

HiberCell to Present Pre-clinical Data on its Novel GCN2 Activator and PERK Inhibitor Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023

Read More

02.22.23 - news

HiberCell Maps Forward Path for Novel GCN2 Activator, HC-7366 in Acute Myeloid Leukemia (AML)

Read More

01.24.23 - publication

Activation of GCN2 by HC-7366 results in significant anti-tumor efficacy

Poster

Read More

11.30.22 - publication

Novel GCN2 Modulator HC-7366 Inhibits Myeloid-derived Suppressor Cells and Reduces Pulmonary Metastases

Poster

Read More

11.30.22 - publication

HC-5404 Demonstrates Immune-activation and Anti-tumor Efficacy

Poster

Read More

11.02.22 - news

HiberCell to Present Preclinical Data from Novel GCN2 Activator and PERK Inhibitor Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Read More

10.28.22 - publication

Optimization of a Novel Mandelamide-Derived Pyrrolopyrimidine Series of PERK Inhibitors

Publication

Read More

03.09.22 - publication

Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer

Publication

Read More

02.24.22 - news

HiberCell Initiates its Phase 1a/b Clinical Trial of HC-7366 in Patients with Advanced Solid Tumors

Read More

09.24.21 - publication

Targeting the Integrated Stress Response in Cancer Therapy

Publication

Read More

09.08.21 - news

HiberCell Receives Fast Track Designation from FDA for First-in-Human Studies of PERK Inhibitor (PERKi) HC-5404-FU

Read More

08.16.21 - news

HiberCell Expands Translational Oncology Toolbox by Acquiring Genuity Science, Inc.

Read More

07.30.21 - publication

PERK inhibition blocks metastasis initiation by limiting UPR-dependent survival of dormant disseminated cancer cells

Publication

Read More

06.10.21 - news

HiberCell Initiates Phase 1a Clinical Trial of HC-5404-FU, an ER Stress Modulator

Read More

05.19.21 - news

HiberCell Closes $67.4 Million Series B Financing and Secures $30 Million Debt Facility from Hercules Capital

Read More

02.21.21 - publication

Endoplasmic reticulum stress signals in the tumour and its microenvironment

Publication

Read More

01.21.21 - news

HiberCell Expands Scientific Advisory Board with Appointment of Lisa M. Coussens, Ph.D., and Ronald Wek, Ph.D.

Read More

12.04.19 - news

Nature Sponsored Feature – Pioneering the Discovery and Development of Novel Therapeutics to Prevent Metastasis

Read More

02.07.19 - news

STAT – New York biotech debuts, targeting dormant metastatic cancer cells

Read More

02.07.19 - news

FierceBiotech – Biotech HiberCell launches with $60M+ to combat cancer relapse and metastasis

Read More

02.07.19 - news

Endpoints – Arch joins Celgene, China investors bankrolling a pioneering New York biotech startup focused on a new approach to metastasis

Read More

02.07.19 - news

HiberCell Launches to Prevent Cancer Relapse and Metastasis with Novel Therapeutics

Read More

09.28.18 - news

How dormant cancer persists and reawakens

Read More

12.13.16 - news

Mechanism of early dissemination and metastasis in Her2+ mammary cancer

Read More